Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
SANOFI INDIA TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SANOFI INDIA Dec-23 |
TEVA PHARMA Dec-13 |
SANOFI INDIA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 8,278 | 3,484 | - | |
Low | Rs | 5,240 | 3,026 | - | |
Sales per share (Unadj.) | Rs | 1,238.0 | 1,999.3 | - | |
Earnings per share (Unadj.) | Rs | 261.8 | 124.9 | - | |
Cash flow per share (Unadj.) | Rs | 279.0 | 286.5 | - | |
Dividends per share (Unadj.) | Rs | 167.00 | 109.33 | - | |
Avg Dividend yield | % | 2.5 | 3.4 | 73.6% | |
Book value per share (Unadj.) | Rs | 411.2 | 2,220.8 | - | |
Shares outstanding (eoy) | m | 23.03 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.5 | 1.6 | 335.3% | |
Avg P/E ratio | x | 25.8 | 26.1 | 99.1% | |
P/CF ratio (eoy) | x | 24.2 | 11.4 | 213.2% | |
Price / Book Value ratio | x | 16.4 | 1.5 | 1,121.6% | |
Dividend payout | % | 63.8 | 87.5 | 72.9% | |
Avg Mkt Cap | Rs m | 155,659 | 2,760,189 | 5.6% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 3,706 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,721.8 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,356.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 28,511 | 1,695,406 | 1.7% | |
Other income | Rs m | 665 | 0 | - | |
Total revenues | Rs m | 29,176 | 1,695,406 | 1.7% | |
Gross profit | Rs m | 8,203 | 464,288 | 1.8% | |
Depreciation | Rs m | 396 | 137,041 | 0.3% | |
Interest | Rs m | 17 | 33,301 | 0.1% | |
Profit before tax | Rs m | 8,455 | 293,946 | 2.9% | |
Minority Interest | Rs m | 0 | 1,335 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,960 | -0.0% | |
Tax | Rs m | 2,426 | -3,589 | -67.6% | |
Profit after tax | Rs m | 6,029 | 105,911 | 5.7% | |
Gross profit margin | % | 28.8 | 27.4 | 105.1% | |
Effective tax rate | % | 28.7 | -1.2 | -2,350.2% | |
Net profit margin | % | 21.1 | 6.2 | 338.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 31,314 | 1,145,071 | 2.7% | |
Current liabilities | Rs m | 25,347 | 998,599 | 2.5% | |
Net working cap to sales | % | 20.9 | 8.6 | 242.2% | |
Current ratio | x | 1.2 | 1.1 | 107.7% | |
Inventory Days | Days | 159 | 91 | 174.9% | |
Debtors Days | Days | 17 | 96 | 17.6% | |
Net fixed assets | Rs m | 15,714 | 553,757 | 2.8% | |
Share capital | Rs m | 230 | 4,173 | 5.5% | |
Net worth | Rs m | 9,469 | 1,883,275 | 0.5% | |
Long term debt | Rs m | 0 | 866,899 | 0.0% | |
Total assets | Rs m | 47,028 | 3,874,547 | 1.2% | |
Interest coverage | x | 498.4 | 9.8 | 5,071.2% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.4 | 138.5% | |
Return on assets | % | 12.9 | 3.6 | 357.8% | |
Return on equity | % | 63.7 | 5.6 | 1,132.2% | |
Return on capital | % | 89.5 | 4.9 | 1,814.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,304 | 270,160 | 0.9% | |
From Investments | Rs m | 375 | -95,729 | -0.4% | |
From Financial Activity | Rs m | -8,783 | -324,075 | 2.7% | |
Net Cashflow | Rs m | -6,104 | -149,644 | 4.1% |
Compare SANOFI INDIA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare SANOFI INDIA With: SUPRIYA LIFESCIENCE PIRAMAL PHARMA KOPRAN. SHARON BIO-MEDICINE VENUS REMEDIES
On Friday, Indian share markets traded on a positive note throughout the trading session and ended higher.